Second RNAi-based drug gains FDA approval, targeting rare genetic condition causing severe abdominal pain

it alny newscom
Image: Kris Tripplaar/Sipa USA

The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran.

The medicine is intended to treat a rare genetic condition called acute hepatic porphyria that can cause attacks of severe abdominal pain. The drug, which will be branded as Givlaari, will cost $575,000 per year, the company announced [November 20]; after discounts, it expects the average price to be $442,000 per year. Each vial of the drug will cost $39,000.

RNA interference, or RNAi, lets scientists mute genes that aren’t functioning properly. Although scientists pioneered the technique decades ago, the FDA only approved the first RNAi-based drug, another of Alnylam’s, last year.

Related article:  Were ‘crucial contributors’ snubbed in awarding Nobel prize for cancer immunotherapy?


The drug’s approval is a good sign for other companies developing drugs based on the RNAi technique. The drug is the first to use a type of sugar called GalNAc that allows more precise delivery of drugs to liver cells — which could, potentially, reduce serious side effects associated with the drug going elsewhere in the body.

“This really is an important milestone for the whole field,” [Alnylam CEO John] Maraganore said.

Read full, original post: FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...

Gilles-Éric Séralini: Activist professor and face of anti-GMO industry

The French biologist and his research team--funded by the Rodale ...
vandana shiva

Vandana Shiva: ‘Rock Star’ of GMO protest movement has anti-science history

In a 2012 interview, Bill Moyers referred to Vandana Shiva as ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend